A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7226 participants.

Also called NCT01042769

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,226 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01042769
Other papers using this trial's data
  • Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome Diabetes care, 2018-08 DOI, PubMed 29903845
  • Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial JAMA, 2014-04-16 DOI, PubMed 24682069

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, China, Czechia, Denmark, France, Germany, Grenada, Hungary, India, Ireland, Italy, Malaysia, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, South Korea, Spain, Sweden, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01042769. Randomized; double masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2013-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Aleglitazar
Intervention (Drug)
Placebo
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01042769
Content hash
3b06c9ff67c1543ed489f9e26172af8dc0f2d3706b033f14bd6b4db60d99b181